Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYPT NASDAQ:NVMI NYSE:OUST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYPTEyepoint Pharmaceuticals$10.07-4.8%$9.59$3.91▼$13.98$728.02M1.73604,476 shs785,022 shsNVMINova$262.57+1.9%$255.98$153.99▼$291.99$7.58B1.67274,878 shs576,287 shsOUSTOuster$23.10+0.6%$22.26$5.84▼$31.77$1.24B2.742.09 million shs2.71 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYPTEyepoint Pharmaceuticals-2.85%+7.52%+11.49%+73.30%+17.29%NVMINova-2.19%-5.89%-10.01%+38.14%+41.22%OUSTOuster-4.45%+2.13%+2.45%+164.57%+109.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYPTEyepoint Pharmaceuticals1.8259 of 5 stars3.52.00.00.01.71.70.0NVMINova1.7023 of 5 stars1.42.00.00.03.81.71.9OUSTOuster0.5205 of 5 stars1.42.00.00.01.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYPTEyepoint Pharmaceuticals 3.00Buy$25.78155.99% UpsideNVMINova 2.80Moderate Buy$282.507.59% UpsideOUSTOuster 2.86Moderate Buy$15.24-34.03% DownsideCurrent Analyst Ratings BreakdownLatest EYPT, NVMI, and OUST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025EYPTEyepoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.008/6/2025EYPTEyepoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $23.006/24/2025NVMINovaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$250.00 ➝ $300.006/24/2025NVMINovaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$250.00 ➝ $270.006/17/2025EYPTEyepoint PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$28.006/12/2025OUSTOusterWestpark CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/12/2025OUSTOusterCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$19.005/29/2025EYPTEyepoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.005/16/2025EYPTEyepoint PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.005/9/2025NVMINovaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$290.00 ➝ $280.005/9/2025NVMINovaBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$295.00 ➝ $280.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYPTEyepoint Pharmaceuticals$43.27M16.01N/AN/A$4.93 per share2.04NVMINova$672.40M11.48$7.13 per share36.85$31.69 per share8.29OUSTOuster$117.79M10.54N/AN/A$4.15 per share5.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYPTEyepoint Pharmaceuticals-$130.87M-$2.41N/AN/AN/A-337.93%-61.64%-48.63%N/ANVMINova$183.76M$6.6239.6632.582.2628.46%23.98%16.15%8/7/2025 (Estimated)OUSTOuster-$374.11M-$1.97N/AN/AN/A-106.50%-65.17%-37.02%8/7/2025 (Estimated)Latest EYPT, NVMI, and OUST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025NVMINova$2.05$2.20+$0.15$2.14$214.95 million$219.99 million8/7/2025Q2 2025OUSTOuster-$0.48N/AN/AN/A$33.77 millionN/A5/8/2025Q1 2025NVMINova$2.08$2.18+$0.10$2.03$210.10 million$213.36 million5/7/2025Q1 2025EYPTEyepoint Pharmaceuticals-$0.65-$0.65N/A-$0.65$8.84 million$24.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYPTEyepoint PharmaceuticalsN/AN/AN/AN/AN/ANVMINovaN/AN/AN/AN/AN/AOUSTOusterN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYPTEyepoint PharmaceuticalsN/A7.857.79NVMINovaN/A2.181.74OUSTOusterN/A3.122.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYPTEyepoint Pharmaceuticals99.41%NVMINova82.99%OUSTOuster31.45%Insider OwnershipCompanyInsider OwnershipEYPTEyepoint Pharmaceuticals4.46%NVMINova1.00%OUSTOuster6.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYPTEyepoint Pharmaceuticals12068.81 million65.74 millionOptionableNVMINova4,14929.40 million29.11 millionOptionableOUSTOuster28053.77 million45.88 millionOptionableEYPT, NVMI, and OUST HeadlinesRecent News About These CompaniesOuster, Inc. (OUST) Q2 2025 Earnings Call Transcript2 hours ago | seekingalpha.comOuster, Inc. (OUST) Reports Q2 Loss, Beats Revenue Estimates3 hours ago | zacks.comTrump calls for Intel CEO’s ouster amid alleged $200 million investments in Chinese chip firmsAugust 7 at 8:34 AM | businesstoday.inBTrump team pushes for ouster of top IEA officialAugust 7 at 8:34 AM | eenews.netEFormer House Speaker Paul Ryan on Trump's tariff agenda, Fed independence and BLS chief's ousterAugust 7 at 8:34 AM | msn.comThe Challenges Facing Bangladesh One Year After Hasina’s OusterAugust 6 at 3:41 AM | msn.comTexas AG’s Ultimatum to Missing Democrats: Return or Risk OusterAugust 5 at 5:41 PM | dailysignal.comDIowa Republican targets GOP Sen Joni Ernst for ouster, saying 'she doesn't vote like' RepublicansAugust 5 at 5:41 PM | msn.comOne year after Hasina’s ouster, Yunus announces Bangladesh polls in February 2026August 5 at 5:41 PM | theprint.inTOuster (NYSE:OUST) Trading Up 9.2% - What's Next?August 5 at 5:29 PM | marketbeat.comOuster, Inc. (OUST): A Bull Case TheoryAugust 5 at 3:23 PM | insidermonkey.comJuly Uprising Day: Thousands expected to join rallies, concerts one year after Hasina's ousterAugust 5 at 12:40 PM | tbsnews.netTThousands in Bangladesh celebrate 1st anniversary of Hasina's ousterAugust 5 at 12:40 PM | msn.comBangladesh marks first anniversary of Hasina's ouster, vows democratic renewalAugust 5 at 12:40 PM | msn.comBangladesh marks anniversary of Hasina's ouster with pledges for a stronger democracyAugust 5 at 12:40 PM | msn.comA year after ouster, where is Bangladesh’s Sheikh Hasina?August 5 at 7:39 AM | firstpost.comFA year after ouster, Sheikh Hasina’s sharp attack at ‘unelected’ regime of Yunus: ‘Dark moment in history’August 5 at 7:39 AM | moneycontrol.comSheikh Hasina denounces Yunus’ ‘unelected regime’ in Bangladesh: A timeline of events that led to her ouster a year agoAugust 5 at 7:39 AM | indianexpress.comIThousands join Bangladesh rallies, concerts one year after Hasina's ousterAugust 5 at 7:39 AM | msn.comCAT slams Govt for arbitrary ouster of contractual medical facultyAugust 5 at 2:38 AM | dailyexcelsior.comDEdelstein shares Haredi draft proposal, hours before vote on his ouster as panel headAugust 5 at 2:38 AM | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEYPT, NVMI, and OUST Company DescriptionsEyepoint Pharmaceuticals NASDAQ:EYPT$10.07 -0.51 (-4.82%) Closing price 04:00 PM EasternExtended Trading$10.28 +0.21 (+2.09%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Nova NASDAQ:NVMI$262.57 +4.86 (+1.89%) Closing price 04:00 PM EasternExtended Trading$262.80 +0.23 (+0.09%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nova Ltd. designs, develops, produces, and sells process control systems used in the manufacture of semiconductors in Israel, Taiwan, the United States, China, Korea, and internationally. Its product portfolio includes a set of metrology platforms for dimensional, films, and materials and chemical metrology measurements for process control for various semiconductor manufacturing process steps, including lithography, etch, chemical mechanical planarization, deposition, electrochemical plating, and advanced packaging. The company serves various sectors of the integrated circuit manufacturing industry, including logic, foundries, and memory manufacturers, as well as process equipment manufacturers. Nova Ltd. was formerly known as Nova Measuring Instruments Ltd. and changed its name to Nova Ltd. in July 2021. Nova Ltd. was incorporated in 1993 and is headquartered in Rehovot, Israel.Ouster NYSE:OUST$23.10 +0.13 (+0.57%) Closing price 04:00 PM EasternExtended Trading$27.88 +4.78 (+20.67%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ouster, Inc. provides lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries in Americas, the Asia-Pacific, Europe, the Middle East, and Africa. Its products include high-resolution scanning and solid-state digital lidar sensors, analog lidar sensors, and software solutions. The company offers Ouster Sensor, a scanning sensor; and Digital Flash, a solid-state flash sensor. It also provides surround-view lidar sensors, which include Ouster Gemini, a perception platform for smart infrastructure deployments; and Blue City, a Gemini-powered solution for traffic operations, planning, and safety. The company is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
